The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic ...

Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for its US clinical study of EndoArt, which is currently designated by the FDA ...

Formosa and Rxilient have an exclusive licensing agreement for APP13007 commercialization, including regulatory and sales ...

ViaLase announced the first patient has been treated in its US-based Investigational Device Exemption (IDE) clinical trial ...

Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

Iolyx Therapeutics and Laboratoires Théa (Théa), through support from its subsidiary Théa Open Innovation, have entered into ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

The panel reviews the mechanisms, efficacy, and tolerability of novel treatments, including perfluorohexyloctane (Miebo), ...